NFL Biosciences : Activités & Résultats annuels 2021
28 mars 2022 01h00 HE
|
NFL BIOSCIENCES
NFL Biosciences : Activités & Résultats annuels 2021 Mise en œuvre de l’étude de clinique de Phase II/III du candidat médicament NFL-101 pour le sevrage tabagique : premiers patients recrutés et...
NFL Biosciences: 2021 full-year business and earnings update
28 mars 2022 01h00 HE
|
NFL BIOSCIENCES
NFL Biosciences: 2021 full-year business and earnings update Phase II/III clinical trial rolled out for the drug candidate NFL-101 for smoking cessation: first patients recruited and recruitment...
NFL BIOSCIENCES : accord de co-développement d’un candidat médicament pour réduire la consommation d’alcool
02 févr. 2022 11h45 HE
|
NFL BIOSCIENCES
NFL Biosciences : accord de co-développement d’un candidat médicament pour réduire la consommation d’alcool Accord de co-développement de NFL-301, candidat médicament destiné à réduire la...
NFL BIOSCIENCES: co-development agreement for a drug candidate to reduce alcohol consumption
02 févr. 2022 11h45 HE
|
NFL BIOSCIENCES
NFL Biosciences: co-development agreement for a drug candidate to reduce alcohol consumption Co-development agreement for NFL-301, a drug candidate to reduce alcohol consumption, with plans to...
NFL BIOSCIENCES : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE S2 2021
12 janv. 2022 11h45 HE
|
NFL BIOSCIENCES
NFL BIOSCIENCESBILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE S2 2021 Au titre du contrat de liquidité portant sur les actions de la société NFL Biosciences SA (FR0014003XT0 - ALNFL) confié à Invest...
Nfl Biosciences: Half-Year Review of the Liquidity Agreement for h2 2021
12 janv. 2022 11h45 HE
|
NFL BIOSCIENCES
NFL BIOSCIENCESHALF-YEAR REVIEW OF THE LIQUIDITY AGREEMENT FOR H2 2021 Under the liquidity agreement concerning NFL Biosciences SA shares (FR0014003XT0 - ALNFL), entrusted to Invest Securities, the...
NFL Biosciences : lancement de l’étude clinique de Phase II/III pour le sevrage tabagique
14 déc. 2021 11h45 HE
|
NFL BIOSCIENCES
NFL Biosciences : lancement de l’étude clinique de Phase II/III pour le sevrage tabagique Une étude internationale conduite sur 318 fumeurs sur une durée prévisionnelle de 24 mois 4 centres ouverts...
NFL Biosciences: Phase II/III clinical trial launched for smoking cessation
14 déc. 2021 11h45 HE
|
NFL BIOSCIENCES
NFL Biosciences: Phase II/III clinical trial launched for smoking cessation International trial conducted on 318 smokers over a period of 24 months. Four centers opened simultaneously in France and...
NFL BIOSCIENCES : accord de production de ses principes actifs avec Diverchim
17 nov. 2021 11h45 HE
|
NFL BIOSCIENCES
COMMUNIQUÉ DE PRESSE Montpellier, le 17 novembre 2021 NFL Biosciences : accord de production de ses principes actifs avec Diverchim Une production BPF (Bonnes Pratiques de Fabrication) des...
NFL BIOSCIENCES: agreement signed with Diverchim to manufacture its active ingredients
17 nov. 2021 11h45 HE
|
NFL BIOSCIENCES
Montpellier, November 17, 2021 NFL Biosciences: agreement signed with Diverchim to manufacture its active ingredients Good manufacturing practices (GMP) production of the NFL-101 and NFL-201 active...